TP53 and myelodysplastic syndrome: Based on promising phase I/II data, APR-246, a p53-refolding agent, has been tested in a randomized phase III trial in TP53-mutant MDS, CMML, or AML (<30% blasts) patients in combination with AZA vs. AZA monotherapy.